ME/CFS Genes Study
ME/CFS Genes Study needs you!
Connect with the INIM
Kendall Kendall Village Center Professional Arts Bldg., Suite 111 8501 SW 124th Avenue, Miami, FL 33183 Directions
Ft. Lauderdale-Davie Center for Collaborative Research, 4th Floor 3301 College Avenue Fort Lauderdale, FL 33314 Directions
Schedule an Appointment
Trust your health care to those who teach it.
Call us today to set up an appointment:
Mon-Fri: 9 am - 5 pm
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), as well as other fatigue related illnesses are poorly understood. Individuals can have severe, long-lasting fatigue, which cannot be properly explained through extensive diagnostic procedures. Our research partnership with the CDC, Miami VA, NIH, other universities and Private Institutions furthers the understanding in the medical community as to how these illnesses affect their patients and could be used to develop a better understanding for improved health care.
While there is no direct benefit from participating in some of the below research studies, your participation will be contributing to the knowledge and understanding of these illnesses. With your help, people with ME/CFS or other fatiguing illnesses may be better treated in the future. We thank you in advance for your participation and continued support.
We are currently recruiting ME/CFS patients AND Healthy Controls for this completely web based study to create a one of a kind genetic database for individuals with ME/CFS.
Click here for more information!
In this study, we will focus on antibody-mediated immune responses. Antibodies are extremely important for any immune response. They are produced by activated B cells after which, they are released into circulation. Antibodies are vital for elimination of microbial infections or other perceived foreign antigens and for establishment of immune system memory to previously seen antigens. Antibodies, by themselves, cause very little harm. However, their strength lies in their ability to tag a molecule as harmful, block its function or mark it for elimination. Because different areas of the body are diverse in their form, function and composition, there are different types of antibodies suited for each area. Different antibody types are called isotypes. In our study, we will focus on three isotypes: IgA, IgE and IgG. IgA is used by the immune system in mucosal tissues, including gastrointestinal tract tissue, IgG is used by the immune system in blood and IgE mediates allergic responses. The presence in blood of IgA, IgG or IgE antibodies that bind specific antigens indicates a person is not tolerant to that antigen and they have mounted an immune response to it.
This is a pilot study that will evaluate the frequency of gluten sensitivity in a sample of patients with the diagnosis of Seropositive Rheumatoid Arthritis (RA). RA is an autoimmune disease that is caused by a complex mixture of genetic, environmental and immunologic factors. When these factors are combined, a patient’s immune system develops antibodies to their own cells or proteins, leading to immune system attack (the body is fighting itself). Continuous immune system activation to a patient’s tissue leads to chronic inflammation, resulting in architectural deformation of bone and joints. The systemic inflammation of RA may also involve the heart (and vasculature), lungs, eyes, skin, nerves and most internal organs.
We will test serum samples from the blood of RA patients for the presence of total and wheat-specific IgE antibodies. The presence of these specific IgE antibodies will indicate participant allergic status. The results from this analysis will elucidate the number of RA patients in our study with a true IgE-mediated wheat allergy, as opposed to sensitivity to wheat or gluten. Total IgE and wheat IgE will indicate the levels of allergic IgE antibodies a patient produces to wheat. The presence of wheat IgE antibodies will suggest the participant has a true allergy to wheat as opposed to Celiac Disease or Non Celiac Gluten Sensitivity.
The Institute for Neuro-Immune Medicine (INIM) is conducting a Multi-site research study on behalf of the CDC to better understand the nature of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) with the ultimate goal of improving quality of care available to ME/CFS patients. These studies are being conducted at the INIM's Kendall and Davie locations. Below are the different groups participating in the study. For more information, please contact us at 305-275-5450 or email INIMresearch@nova.edu
Participants enrolled were diagnosed with ME/CFS or Post-Infective Fatigue (PIF), between the ages of 18 and 70 years old and diagnosed with their illness prior to age 62.
Participants enrolled were healthy controls NOT diagnosed with ME/CFS, Fibromyalgia, or PIF and between the ages of 18 and 70. In addition, participants could not be living with someone diagnosed with ME/CFS.
Participants enrolled were diagnosed with Fibromyalgia, between the ages of 18 and 70 years old and were NOT diagnosed with ME/CFS, HIV or Dementia.
Participants enrolled were diagnosed with ME/CFS or Post-Infective Fatigue (PIF) and were unable to leave their homes for office visits without severe consequences. Eligible participants were between the ages of 18 and 70 years old and diagnosed with their illness prior to age 62.
Participants enrolled were diagnosed with ME/CFS or PIF, between the ages of 18 and 70 years old, diagnosed prior to age 62 and had the onset of their illness within the past 2 years.
Participants enrolled were diagnosed with ME/CFS and Post-Infective Fatigue, between the ages of 10 and 17 years old.
Participants enrolled completed Stage 1 of the CDC ME/CFS study and were between the ages of 18 and 70 years old.
In this study, we are interested in better understanding the causes of Gulf War illness symptoms. We are currently recruiting Veterans with Gulf War illness as well as healthy Gulf War-era Veterans.
For more information please contact us at 305-575-7648 or email VHAMIAGWI@va.gov
In this study we are using microarray, a technique which measures expression levels of large numbers of genes, to help better understand and identify the likely causes of Gulf War illness. This method allows researchers to study different genes that affect how the body reacts to rest and exercise and how these differences affect the immune system, endocrine system, and brain. Location: Miami VA Medical Center & University of Miami. We are currently recruiting Women Veterans with Gulf War illness and as well as Women Gulf War-era sedentary Veterans.
This is a systematic assessment and characterization of the therapeutic effects of drugs that impact a specific list of therapeutic targets and are based on prior research. This is study is located at Miami VA Medical Center. We are currently rrecruiting Veterans with Gulf War Illness and Gulf War era healthy controls.
Two natural supplements (Curcumin and Glutathione) have been shown to quiet inflammation. In this study, researchers will test to see which supplements, if any, are beneficial in Gulf War illness. This study is located at the Miami VA Medical Center. We are currently recruiting Veterans with Gulf War Illness between 35-70 years of age.
Purpose of this study is to determine if treatment with ubiquinol, a form of coenzyme Q10, improves the physical function of men and women Veterans suffering from Gulf War illness. We are Located at the Miami VA Medical Center, VA Boston Healthcare System, Minneapolis VA Health Care System, and the James J. Peters VA Medical Center. We are currently recruiting all Gulf War Veterans.
Purpose of this study is to test the safety, effectiveness, and biological response to two medications (Etanercept followed by Mifepristone) in changing your bodies “sick response” of GWI into a more permanently healthy condition. This study is located at the Miami VA Medical Center. We are currently recruiting Male Veterans with Gulf War Illness between 45-70 years of age.
The Gulf War Illness consortium is conducting several clinical trials and interventions aimed at understanding gulf war illness. These clinical trials are funded by the Department of Defense (DoD) and will be conducted at NSU's Institute for Neuro Immune Medicine, Boston University, RTI International, Bronx VAMC, New Jersey War Related Illness and Injury Study Center (WRIISC), and the California U.S. Department of Veterans Affairs War Related Illness and Injury Study Center (WRIISC).
This dosage finding phase I study will evaluate the safety, effectiveness, and biological response to two medications (TNF and Glucocorticoid receptor antagonists) in changing your bodies “sick response” of GWI into a more permanently healthy condition.
This Phase II will follow the most effective of two potential dosing strategies from phase I for TNF and Glucocorticoid receptor antagonists in changing your bodies “sick response” of GWI into a more permanently healthy condition.
We aim to compare the ability of different antioxidants to cross the blood brain barrier and change the oxidative stress state in the CNS as measured by MRS.
In this phase II study, we will build on our findings from the phase I antioxidant study by combining the best of the two antioxidants anticipating that the combination will work synergistically and help to restore central nervous system (CNS) functions and reset homeostasis.